Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIGATEC trial of chimeric anti-Shiga toxin monoclonal antibodies in children with STEC infection and bloody diarrhea
2011-006094-26Phase 2
- Sponsor
- Thallion Pharmaceuticals Inc.
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of caStx1 in Shiga toxin-producing Escherichia coli infection (STEC) and hemolytic uremic syndrome (HUS) (2 cohorts), sponsored by Thallion Pharmaceuticals Inc. Primary endpoint: Safety and tolerability.
02
Drugs
caStx1
03
Conditions
Shiga toxin-producing Escherichia coli infection (STEC)hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on 2011-006094-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006094-26.